share_log

Todd Berard Sells 3,500 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

Financial News Live ·  Jan 28, 2023 05:39

BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) CMO Todd Berard sold 3,500 shares of BioLife Solutions stock in a transaction dated Monday, January 23rd. The shares were sold at an average price of $25.01, for a total value of $87,535.00. Following the completion of the transaction, the chief marketing officer now owns 119,265 shares of the company's stock, valued at approximately $2,982,817.65. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Todd Berard also recently made the following trade(s):

Get BioLife Solutions alerts:
  • On Wednesday, January 18th, Todd Berard sold 6,500 shares of BioLife Solutions stock. The shares were sold at an average price of $25.04, for a total value of $162,760.00.
  • On Wednesday, December 28th, Todd Berard sold 501 shares of BioLife Solutions stock. The shares were sold at an average price of $16.90, for a total value of $8,466.90.
  • On Thursday, November 10th, Todd Berard sold 50 shares of BioLife Solutions stock. The stock was sold at an average price of $23.16, for a total value of $1,158.00.

BioLife Solutions Trading Down 1.3 %

BLFS opened at $23.50 on Friday. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -9.48 and a beta of 1.75. BioLife Solutions, Inc. has a 52 week low of $10.40 and a 52 week high of $31.11. The business's 50 day moving average is $20.52 and its two-hundred day moving average is $21.37. The company has a quick ratio of 2.76, a current ratio of 3.68 and a debt-to-equity ratio of 0.06.

BioLife Solutions (NASDAQ:BLFS – Get Rating) last released its quarterly earnings results on Wednesday, November 9th. The medical equipment provider reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The firm had revenue of $40.75 million for the quarter, compared to analyst estimates of $41.63 million. BioLife Solutions had a negative return on equity of 7.50% and a negative net margin of 67.70%. On average, research analysts predict that BioLife Solutions, Inc. will post -0.63 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BLFS. Stephens decreased their target price on BioLife Solutions to $31.00 in a research note on Wednesday, November 16th. StockNews.com upgraded BioLife Solutions to a "sell" rating in a research note on Monday, November 21st.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in BioLife Solutions by 10.7% during the third quarter. BlackRock Inc. now owns 5,416,115 shares of the medical equipment provider's stock worth $123,217,000 after buying an additional 522,912 shares during the period. Vanguard Group Inc. increased its holdings in shares of BioLife Solutions by 14.8% in the third quarter. Vanguard Group Inc. now owns 2,415,511 shares of the medical equipment provider's stock valued at $54,953,000 after purchasing an additional 311,913 shares during the period. Fred Alger Management LLC increased its holdings in shares of BioLife Solutions by 21.9% in the third quarter. Fred Alger Management LLC now owns 2,163,476 shares of the medical equipment provider's stock valued at $49,219,000 after purchasing an additional 388,642 shares during the period. Millennium Management LLC increased its holdings in shares of BioLife Solutions by 45.3% in the second quarter. Millennium Management LLC now owns 1,560,137 shares of the medical equipment provider's stock valued at $21,545,000 after purchasing an additional 486,631 shares during the period. Finally, Geneva Capital Management LLC increased its holdings in shares of BioLife Solutions by 5.8% in the third quarter. Geneva Capital Management LLC now owns 1,537,636 shares of the medical equipment provider's stock valued at $34,981,000 after purchasing an additional 84,435 shares during the period. Institutional investors and hedge funds own 89.82% of the company's stock.

About BioLife Solutions

(Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Featured Articles

  • Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment